MedTrace Logo

Odiparcil For The Prevention Of Venous Thromboembolism

NCT00244725 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 961

Last updated 2017-05-02

Study results available
· View outcomes & findings →

Summary

Odiparcil is being studied to determine if it can prevent blood clots from forming after a total knee replacement and also to prove that odiparcil is safe.

Conditions

Interventions

DRUG

Odiparcil

DRUG

Warfarin

DRUG

Coumadin

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2006-09-30
Completion
2006-09-30

Countries

  • United States
  • Australia
  • Brazil
  • Canada
  • India
  • Israel
  • Latvia
  • Lithuania
  • Poland
  • Russia
  • South Africa
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00244725 on ClinicalTrials.gov